Ibrolipim

Ibrolipim
Names
IUPAC name
diethyl {4-[(4-bromo-2-cyanophenyl)carbamoyl]benzyl}phosphonate
Identifiers
3D model (Jmol) Interactive image
ChemSpider 116297 YesY
ECHA InfoCard 100.162.319
KEGG D03747 YesY
PubChem 131601
UNII 07H1561618 YesY
Properties
C19H20BrN2O4P
Molar mass 451.25
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Ibrolipim (NO-1886) is a cholesterol lowering drug from the statin family, which acts as a lipoprotein lipase activator. The discovery of the “statin” mevalonic acid synthesis inhibitors focused new attention on control of blood lipid levels as a measure to stave off heart disease. A number of compounds have been found that treat elevated lipid levels by other diverse mechanisms. The phosphonic acid derivative ibrolipim is believed to lower those levels by accelerating fatty acid oxidation.[1]

References

  1. Yin W, Tsutsumi K (2003). "Lipoprotein lipase activator NO-1886". Cardiovascular Drug Reviews. 21 (2): 133–42. doi:10.1111/j.1527-3466.2003.tb00111.x. PMID 12847564.
This article is issued from Wikipedia - version of the 5/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.